Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance

Marc Noguera-Julian, Dianna Edgil, P. Richard Harrigan, Paul Sandstrom, Catherine Godfrey, Roger Paredes

    Research output: Contribution to journalArticleResearchpeer-review

    26 Citations (Scopus)

    Abstract

    © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. High-quality, simplified, and low-cost human immunodeficiency virus (HIV) drug resistance tests that are able to provide timely actionable HIV resistance data at individual, population, and programmatic levels are needed to confront the emerging drug-resistant HIV epidemic. Next-generation sequencing technologies embedded in automated cloud-computing analysis environments are ideally suited for such endeavor. Whereas NGS can reduce costs over Sanger sequencing, automated analysis pipelines make NGS accessible to molecular laboratories regardless of the available bioinformatic skills. They can also produce highly structured, high-quality data that could be examined by healthcare officials and program managers on a real-time basis to allow timely public health action. Here we discuss the opportunities and challenges of such an approach.
    Original languageEnglish
    Pages (from-to)S829-S833
    JournalJournal of Infectious Diseases
    Volume216
    DOIs
    Publication statusPublished - 1 Jan 2017

    Keywords

    • Bioinformatics
    • HIV resistance
    • NGS
    • Public health.
    • Surveillance

    Fingerprint Dive into the research topics of 'Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance'. Together they form a unique fingerprint.

    Cite this